Anaptysbio, Inc
ANAB Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$48.77
KIRA · Stoqly’s AI analyst, in plain words
- Anaptysbio, Inc had $235M of revenue in fiscal 2025, up 157.0% on the year before. Over five years, revenue changed +25.6% a year on average.
- Its operating margin was 96.7%, up 24.2 pts: of every 100 in sales, about 97 is left after running the business.
- Anaptysbio, Inc lost $13.2M in fiscal 2025.
- Free cash flow was $19.6M in fiscal 2025, 8.4% of revenue.
- Anaptysbio, Inc returned $68.6M to shareholders in fiscal 2025, 350% of free cash flow. The diluted share count rose 2.3%.
Market cap
$1.5B
P/E
—
Revenue
$235M
Net income
−$13.2M
Free cash flow
$19.6M
Operating margin
96.7%
Anaptysbio, Inc in 30 seconds · fiscal 2025
Are sales growing?
+157.0%
Yes. Sales grew 157.0% last year.
Does it make a profit?
−5.6%
No. It lost money last year.
Does profit turn into cash?
8.4%
Partly. 8.4% of sales ends up as free cash.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Anaptysbio, Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-KT · Sep 21, 2026
- Legal name
- ANAPTYSBIO, INC
- CIK
- 0001370053
Anaptysbio, Inc · ANAB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $63.2M | $10.3M | $17.2M | $91.3M | $235M |
| Revenue growth | −15.8% | −83.7% | 66.8% | 432.0% | 157.0% |
| Operating margin | −89.9% | −1,119.4% | −958.3% | 72.5% | 96.7% |
| Net income | −$57.8M | −$129M | −$164M | −$145M | −$13.2M |
| Net margin | −91.5% | −1,251.3% | −953.7% | −159.1% | −5.6% |
| Diluted EPS | −$2.11 | −$4.57 | −$6.08 | −$4.92 | −$0.44 |
| Cash | |||||
| Cash from operations | −$45.9M | −$73.6M | −$121M | −$135M | $19.7M |
| Capital expenditure | $1.4M | $0.4M | $0.8M | $0.4M | $0.1M |
| Free cash flow | −$47.3M | −$74.0M | −$122M | −$136M | $19.6M |
| FCF margin | −74.8% | −718.9% | −708.8% | −148.7% | 8.4% |
| Share buybacks | $0.0M | $0.0M | $50.0M | $0.5M | $68.6M |
| Share count change | 0.5% | 2.7% | −4.4% | 9.7% | 2.3% |
| Debt and strength | |||||
| Cash and short-term investments | $548M | $441M | $391M | $285M | $212M |
| Shareholders' equity | $356M | $262M | $88.1M | $70.9M | $37.2M |
| Current ratio | 34.4x | 17.2x | 10.9x | 9.5x | 9.1x |
| Returns and quality | |||||
| Return on equity | −15.3% | −41.6% | −93.4% | −182.7% | −24.5% |
| Return on tangible equity | −16.2% | −49.1% | −185.7% | −204.9% | −35.6% |
| Piotroski F-score | 2 | 1 | 3 | 3 | 4 |
| Altman Z'' | 4.6 | 1.6 | −1.3 | 1.2 | 3.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$9.8M
8 insiders
Of sales under plans
41%
$4.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Anaptysbio, Inc · ANAB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $48.77 a share, the company is worth $1.5B.
Source: SEC EDGAR XBRL filings (CIK 0001370053). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.